If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBraveheart Inv Regulatory News (BRH)

Share Price Information for Braveheart Inv (BRH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.25
Bid: 7.00
Ask: 7.50
Change: 0.50 (7.41%)
Spread: 0.50 (7.143%)
Open: 6.75
High: 7.25
Low: 6.75
Prev. Close: 6.75
BRH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Placing and subscription to raise £750,000

20 Sep 2022 07:00

RNS Number : 8406Z
Braveheart Investment Group plc
20 September 2022
 

Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the UK Market Abuse Regulation. With the publication of this announcement, this information is now considered to be in the public domain.

 

20 September 2022

 

Braveheart Investment Group Plc

("Braveheart", the "Company" or the "Group")

 

Placing and subscription to raise £750,000

 

Braveheart Investment Group (AIM: BRH), announces that the Company has raised £750,000 (before expenses) by way of a placing of and subscription for new ordinary shares of 2p each ("Ordinary Shares") in the Company (together, the "Fundraise"), at an issue price of 10.25p pence per share (the "Issue Price").

 

The Company has issued 1,951,220 new Ordinary Shares ("Placing Shares") at the Issue Price pursuant to a placing, raising gross proceeds of £200,000.05 before expenses (the "Placing"). The Placing has been arranged by Peterhouse Capital Limited.

 

In addition, the Company has entered into a direct subscription with Trevor Brown, Chief Executive Officer, for a total of 5,365,853 new Ordinary Shares (the "Subscription Shares"), raising a total of £550,000 (the "Subscription"). Trevor Brown has undertaken to the Company that he will not dispose of any of the Subscription Shares for a period of one year from the date of admission to trading on the AIM market of the Subscription Shares, without the prior written consent of the Company and the Company's Nomad.

 

A total of 7,317,073 new Ordinary Shares (together the "Fundraise Shares") are to be issued at the Issue Price. The Fundraise has been conducted utilising the Company's existing share authorities granted at the Annual General Meeting of the Company held on 13 July 2022. The Fundraise is conditional, inter alia, on admission of the Fundraise Shares to trading on AIM ("Admission") becoming effective.

 

The Fundraise has been undertaken by the Company to enable it to be in sufficient funds to be able to support its current investee companies from a position of strength should the need arise for further funds and to be able to make opportunistic new investments.

 

Director's holding

 

Trevor Brown's total beneficial interest following this transaction will be 12,429,424 Ordinary Shares, representing approximately 19.51% of the voting rights in the Company's enlarged share capital following the issue of the Subscription Shares. The FCA notification, made in accordance with the requirements of the UK Market Abuse Regulation, is appended below.

 

Related Party Transaction

 

The subscriber for the Subscription Shares is Trevor Brown, who is the CEO and a Director of Braveheart and, therefore, the transaction is treated as a related party transaction under the AIM rules. The independent directors, being Qu Li, Susan Hagan and Vivian Hallam, consider, having consulted with Allenby Capital Limited, the Company's Nominated Adviser, that the terms of the Subscription and the issue of the Subscription Shares are fair and reasonable insofar as the shareholders of Braveheart are concerned.

 

Admission of the Fundraise Shares

 

Application has been made for the 7,317,073 Fundraise Shares to be admitted to trading on AIM ("Admission"), which is expected to take place on or around 26 September 2022. Once issued, the Fundraise Shares will rank pari passu in all respects with the existing Ordinary Shares of the Company.

 

Total Voting Rights

 

Following Admission, the Company's issued ordinary share capital will consist of 63,723,489 Ordinary Shares, all of which carry one voting right per share. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares and voting rights in the Company will be 63,723,489. With effect from Admission, this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

For further information: 

Braveheart Investment Group plc

Tel: 01738 587555

Trevor Brown, Chief Executive Officer

Viv Hallam, Executive Director

Allenby Capital Limited (Nominated Adviser and Joint Broker)

Tel: 020 3328 5656

David Worlidge / James Reeve / George Payne

Peterhouse Capital Limited (Joint Broker)

Tel: 020 7469 0936

Heena Karani / Lucy Williams

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Trevor Brown

 

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive Officer

 

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Braveheart Investment Group plc

b)

 

LEI

 

2138006HQ3COMU626I61

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary shares of 2 pence each in Braveheart Investment Group plc

 

 

GB00B13XV322

b)

 

Nature of the transactions

 

issue of new Ordinary Shares

c)

 

Price(s) and volume(s)

 

 

Price(s)

 

10.25p

 

 

Volume(s)

 

5,365,853

d)

 

Aggregated information

- Aggregated volume

- Price

- Principal amount

 

 

5,365,853

10.25p

£ 549,999.93

e)

 

Dates of the transaction

 

16 September 2022

f)

Place of transaction

Outside a trading venue

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOESFLFEAEESEFU
Date   Source Headline
5th Nov 20204:36 pmRNSPrice Monitoring Extension
4th Nov 20208:52 amRNSExercise of Warrants and Issue of Equity
3rd Nov 202011:06 amRNSSecond Price Monitoring Extn
3rd Nov 202011:00 amRNSPrice Monitoring Extension
2nd Nov 20202:06 pmRNSSecond Price Monitoring Extn
2nd Nov 20202:01 pmRNSPrice Monitoring Extension
29th Oct 20204:40 pmRNSSecond Price Monitoring Extn
29th Oct 20204:35 pmRNSPrice Monitoring Extension
29th Oct 20207:00 amRNSIssue of shares to certain directors and TVR
27th Oct 20202:05 pmRNSSecond Price Monitoring Extn
27th Oct 20202:00 pmRNSPrice Monitoring Extension
23rd Oct 20207:00 amRNSUpdate on Pharm2Farm’s COVID-19 mask project
19th Oct 20202:06 pmRNSSecond Price Monitoring Extn
19th Oct 20202:00 pmRNSPrice Monitoring Extension
19th Oct 202012:42 pmRNSFurther re. Conditional Sale of Pharm2Farm holding
19th Oct 202012:35 pmRNSPublication of Circular and Notice of GM
16th Oct 20207:00 amRNSFurther update re Paraytec Limited
8th Oct 20204:09 pmRNSUpdate on Pharm2Farm
5th Oct 202011:20 amRNSFurther update re Paraytec Limited
29th Sep 20204:40 pmRNSSecond Price Monitoring Extn
29th Sep 20204:35 pmRNSPrice Monitoring Extension
24th Sep 20207:00 amRNSUpdate on Phasefocus Holdings Limited
18th Sep 20207:00 amRNSUpdate on the Pharm2Farm anti-viral mask project
8th Sep 202012:18 pmRNSResult of AGM
3rd Sep 20207:00 amRNSFurther re Paraytec Limited
28th Aug 20205:00 pmRNSTotal Voting Rights
21st Aug 20205:09 pmRNSConditional Sale of Pharm 2 Farm Limited holding
20th Aug 20201:04 pmRNSHolding(s) in Company
5th Aug 20204:41 pmRNSSecond Price Monitoring Extn
5th Aug 20204:35 pmRNSPrice Monitoring Extension
5th Aug 20207:00 amRNSFurther re Paraytec Limited
4th Aug 20207:00 amRNSFinal Results
23rd Jul 202011:00 amRNSPrice Monitoring Extension
21st Jul 20204:41 pmRNSSecond Price Monitoring Extn
21st Jul 20204:36 pmRNSPrice Monitoring Extension
13th Jul 20207:18 amRNSParticipation in RMS placing
7th Jul 20207:00 amRNSFurther re Paraytec Limited
1st Jul 20202:31 pmRNSHolding(s) in Company
30th Jun 20205:00 pmRNSTotal Voting Rights
30th Jun 20203:00 pmRNSAcquisition of 18.1% interest in RMS
19th Jun 20202:29 pmRNSOperational Update
9th Jun 20207:00 amRNSFurther re Paraytec Limited
8th Jun 20207:00 amRNSHolding(s) in Company
5th Jun 202012:44 pmRNSDirector/PDMR Shareholding
5th Jun 20207:00 amRNSAcquisition of Additional PhaseFocus Shares
3rd Jun 20209:05 amRNSSecond Price Monitoring Extn
3rd Jun 20209:00 amRNSPrice Monitoring Extension
3rd Jun 20207:00 amRNSDirector/PDMR Shareholding
2nd Jun 20204:41 pmRNSSecond Price Monitoring Extn
2nd Jun 20204:36 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.